Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most core label claims (indications, formulation, MoA as CGRP receptor antagonist, and dosing) align with the provided prescribing information; however, multiple safety/efficacy mechanistic and adverse-effect claims are not supported by the supplied label text, and the hypersensitivity risk statement is only partially supported as phrased.
Category Scores
Accurate Statements
Nurtec ODT is approved for the acute treatment of migraine with or without aura in adults.
Supported by 1.1 Acute Treatment of Migraine (Indications and Usage).
Nurtec ODT is indicated for the preventive treatment of episodic migraine in adults.
Supported by 1.2 Preventive Treatment of Episodic Migraine (Indications and Usage).
Nurtec ODT contains rimegepant.
Supported by 11 Description (rimegepant sulfate).
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Supported by 12.1 Mechanism of Action and 11 Description.
Nurtec ODT can be used for both acute and preventive migraine treatment.
Supported by 1.1 (acute indication), 1.2 (preventive indication), and referenced dosing section(s) in 2 Dosage and Administration.
For acute treatment, the recommended dose is 75 mg taken as needed for migraine.
Supported by 2.1 Recommended Dosing for Acute Treatment of Migraine.
For preventive treatment, the recommended dose is 75 mg taken every other day.
Supported by 2.2 Recommended Dosing for Preventive Treatment of Episodic Migraine.
Unsupported Statements
By blocking the CGRP receptor, rimegepant is thought to prevent or relieve migraine pain.
Not supported by the provided label text sections (the label excerpt includes CGRP receptor antagonist and does not state this specific 'thought to prevent or relieve migraine pain' mechanism wording).
The most common side effects reported in clinical trials include nausea.
No supported label text provided identifying 'most common' adverse reactions or nausea.
The most common side effects reported in clinical trials include upper abdominal pain.
No supported label text provided identifying 'most common' adverse reactions or upper abdominal pain.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Acute dosing limit/safety statement: maximum dose in a 24-hour period (75 mg) and that safety of using more than 18 doses in a 30-day period has not been established.
Importance:
Moderate
Hypersensitivity reactions details: seriousness (e.g., anaphylaxis, dyspnea, rash), possibility of delayed onset, and instruction to discontinue and initiate appropriate therapy if hypersensitivity occurs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about 'most common' adverse reactions (nausea and upper abdominal pain) could mislead risk expectations; hypersensitivity reactions are supported, but the statement 'rare potential serious risks' is not fully supported by the provided label excerpts as phrased.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Mechanistic phrasing and adverse reaction frequency/typicality statements are not supported by the provided label text; hypersensitivity risk wording ('rare') is only partially supported.
Suggested Improvement
Remove or rephrase unsupported items (mechanism 'thought to prevent or relieve migraine pain' and 'most common' side effect frequency claims). If mentioning hypersensitivity, align wording to the label (serious hypersensitivity incl. anaphylaxis/dyspnea/rash, delayed reactions, and discontinuation guidance). Include the acute maximum dose and the 18-doses/30-day safety-not-established statement.